1. Home
  2. DVAX vs GRC Comparison

DVAX vs GRC Comparison

Compare DVAX & GRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dynavax Technologies Corporation

DVAX

Dynavax Technologies Corporation

HOLD

Current Price

$10.94

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo Gorman-Rupp Company (The)

GRC

Gorman-Rupp Company (The)

HOLD

Current Price

$46.06

Market Cap

1.2B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
DVAX
GRC
Founded
1996
1933
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Fluid Controls
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.2B
IPO Year
2004
N/A

Fundamental Metrics

Financial Performance
Metric
DVAX
GRC
Price
$10.94
$46.06
Analyst Decision
Buy
Analyst Count
4
0
Target Price
$26.50
N/A
AVG Volume (30 Days)
1.7M
80.4K
Earning Date
11-05-2025
10-24-2025
Dividend Yield
N/A
1.64%
EPS Growth
N/A
31.51
EPS
N/A
1.91
Revenue
$330,514,000.00
$678,522,000.00
Revenue This Year
$24.63
$4.94
Revenue Next Year
$15.85
$4.02
P/E Ratio
N/A
$24.18
Revenue Growth
26.73
3.19
52 Week Low
$9.20
$30.87
52 Week High
$14.63
$49.25

Technical Indicators

Market Signals
Indicator
DVAX
GRC
Relative Strength Index (RSI) 50.47 55.38
Support Level $10.79 $45.09
Resistance Level $11.10 $46.94
Average True Range (ATR) 0.31 1.26
MACD -0.07 0.16
Stochastic Oscillator 30.00 82.09

Price Performance

Historical Comparison
DVAX
GRC

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

About GRC Gorman-Rupp Company (The)

Gorman-Rupp Co designs, manufactures, and globally sells pumps & pump systems for use in water, wastewater, construction, dewatering, industrial, petroleum, original equipment, agriculture, fire protection, heating, ventilating & air conditioning, military, and other liquid-handling applications. It operates in one business segment, the manufacture & sale of pumps and pump systems, and generates revenue from the same. Geographically, it generates the majority of revenue from the United States.

Share on Social Networks: